N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Phase 1 Withdrawn
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Phase 1 Withdrawn
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
Phase 1 Withdrawn
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
Phase 1 Withdrawn
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
Phase 1 Withdrawn
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
Phase 1 Withdrawn
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Phase 1 Withdrawn
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Phase 1 Withdrawn
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Withdrawn
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Phase 1 Withdrawn
Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma
Phase 1 Withdrawn
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Phase 1 Withdrawn
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Phase 1 Withdrawn
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
Phase 1 Withdrawn
Oxaloacetate in Myasthenia Gravis
Phase 1 Withdrawn
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
Phase 1 Withdrawn
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Phase 1 Withdrawn
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Withdrawn
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Phase 1 Withdrawn
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Phase 1 Withdrawn
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Phase 1 Withdrawn
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Phase 1 Withdrawn
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Phase 1 Withdrawn
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Phase 1 Withdrawn
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Phase 1 Withdrawn
Antitumor-B KAC PK Study
Phase 1 Withdrawn
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
Phase 1 Withdrawn
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Phase 1 Withdrawn
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Phase 1 Withdrawn
AcTRESS
Phase 1 Withdrawn
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 Withdrawn
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Phase 1 Withdrawn
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Phase 1 Withdrawn
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Phase 1 Withdrawn
IIT PH1 KDS-1001 in Patients With CML
Phase 1 Withdrawn
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1 Withdrawn
LOKI
Phase 1 Withdrawn
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
Phase 1 Withdrawn
Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors
Phase 1 Withdrawn
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
Phase 1 Withdrawn
pediTACTAL
Phase 1 Withdrawn
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Phase 1 Withdrawn
StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord
Phase 1 Withdrawn
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1 Withdrawn
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
Phase 1 Withdrawn
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Phase 1 Withdrawn
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
Phase 1 Withdrawn